Oxford Immunotec today announced the appointment of Phill Keefe, previously the Company’s Chief Operations Officer, as CEO. Keefe succeeds founder Dr. Peter Wrighton-Smith who will step down after 20 years as CEO of Oxford Immunotec.
Keefe joined Oxford Immunotec in 2019 after nearly 25 years in the Diagnostics and Medical Devices industry. As COO, Keefe’s leadership has driven the continuous transformation of Oxford Immunotec, including the execution of operational strategies around scaling the business, improving the quality of the business, and improving the economics for the business and for the customers. His successes across product development include delivering multiple automation solutions to customers and the rapid delivery of new products in identifying and monitoring individuals with a T cell immune response to COVID-19 vaccination or SARS-CoV-2 infection.
“I speak for everyone at Oxford Immunotec in thanking Peter for his tireless dedication to the Company and his leadership,” said Keefe. “I am honored to assume this new role and am grateful to be able to leverage my experience to help shape the organisation’s future.”
“I remain as excited about Oxford Immunotec as I was when it started and am incredibly proud of what our teams and partners have accomplished in detecting infectious disease and ultimately saving lives all around the world,” said Dr. Peter Wrighton-Smith. “With our core expertise and reputation in T cell immunology firmly established, now is the right time to appoint new leadership to continue accelerating the Company’s growth journey.”
